强生竞标收购TARIS公司,以获得其膀胱癌新型靶向递药技术

2019-12-24 不详 MedSci原创

强生公司(Johnson&Johnson)已竞标美国生物技术公司TARIS Biomedical,以追求在膀胱癌中占有更大的市场份额,但未公开报价。

强生公司(Johnson&Johnson)已竞标美国生物技术公司TARIS Biomedical,以追求在膀胱癌中占有更大的市场份额,但未公开报价。

TARIS Biomedical专业从事新型药物输送技术的开发,包括膀胱癌的药物递送。其主要候选人TAR-200是基于硅基药物输送系统,将药物连续释放到膀胱中靶向治疗。

Janssen肿瘤学全球治疗负责人Peter Lebowitz表示:"TARIS技术提供了一流的平台,可为局部膀胱癌患者提供新颖的局部治疗药物。"

他补充说:"与TARIS团队一起,我们期待推进完整的治疗方案,以期尽早介入膀胱癌,改善患者的预后并最终提供治疗方法。"

TARIS将留在美国成为Janssen(强生制药部门)肿瘤研发治疗领域的一部分。

强生在膀胱癌领域拥有很强的实力,其膀胱癌药物Balversa(erdafitinib)于今年早些时候在美国获得批准。

该药物针对携带成纤维细胞生长因子(FGFR)突变的膀胱癌患者。这些遗传突变存在于大约五分之一的复发和难治膀胱癌患者中。

膀胱癌每年影响近55万人,其中很大一部分以死亡告终。尽管它影响了很大一部分人,但事实证明,膀胱癌对新药疗法具有显着的抵抗力。尽管出现了使用检查点抑制剂的免疫疗法,在过去几年中改变了某些膀胱癌患者的前景,但大多数患者对该治疗无反应。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1819854, encodeId=3c3f1819854cf, content=<a href='/topic/show?id=946299954c2' target=_blank style='color:#2F92EE;'>#靶向递药技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99954, encryptionId=946299954c2, topicName=靶向递药技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Jun 16 05:34:00 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795553, encodeId=00a41e95553c2, content=<a href='/topic/show?id=714b1e138e7' target=_blank style='color:#2F92EE;'>#TARIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17138, encryptionId=714b1e138e7, topicName=TARIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76d3356, createdName=tongyongming, createdTime=Sun May 24 14:34:00 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271716, encodeId=9afa12e1716b6, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Dec 26 12:34:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039960, encodeId=0f101039960bd, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Wed Dec 25 00:34:00 CST 2019, time=2019-12-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1819854, encodeId=3c3f1819854cf, content=<a href='/topic/show?id=946299954c2' target=_blank style='color:#2F92EE;'>#靶向递药技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99954, encryptionId=946299954c2, topicName=靶向递药技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Jun 16 05:34:00 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795553, encodeId=00a41e95553c2, content=<a href='/topic/show?id=714b1e138e7' target=_blank style='color:#2F92EE;'>#TARIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17138, encryptionId=714b1e138e7, topicName=TARIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76d3356, createdName=tongyongming, createdTime=Sun May 24 14:34:00 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271716, encodeId=9afa12e1716b6, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Dec 26 12:34:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039960, encodeId=0f101039960bd, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Wed Dec 25 00:34:00 CST 2019, time=2019-12-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1819854, encodeId=3c3f1819854cf, content=<a href='/topic/show?id=946299954c2' target=_blank style='color:#2F92EE;'>#靶向递药技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99954, encryptionId=946299954c2, topicName=靶向递药技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Jun 16 05:34:00 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795553, encodeId=00a41e95553c2, content=<a href='/topic/show?id=714b1e138e7' target=_blank style='color:#2F92EE;'>#TARIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17138, encryptionId=714b1e138e7, topicName=TARIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76d3356, createdName=tongyongming, createdTime=Sun May 24 14:34:00 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271716, encodeId=9afa12e1716b6, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Dec 26 12:34:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039960, encodeId=0f101039960bd, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Wed Dec 25 00:34:00 CST 2019, time=2019-12-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1819854, encodeId=3c3f1819854cf, content=<a href='/topic/show?id=946299954c2' target=_blank style='color:#2F92EE;'>#靶向递药技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99954, encryptionId=946299954c2, topicName=靶向递药技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Jun 16 05:34:00 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795553, encodeId=00a41e95553c2, content=<a href='/topic/show?id=714b1e138e7' target=_blank style='color:#2F92EE;'>#TARIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17138, encryptionId=714b1e138e7, topicName=TARIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76d3356, createdName=tongyongming, createdTime=Sun May 24 14:34:00 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271716, encodeId=9afa12e1716b6, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Dec 26 12:34:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039960, encodeId=0f101039960bd, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Wed Dec 25 00:34:00 CST 2019, time=2019-12-25, status=1, ipAttribution=)]
    2019-12-25 留走人康

    膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效

    0

相关资讯

重锤!美国对多家阿片类药物厂商展开刑事调查 强生、梯瓦……

阿片药物成瘾在美国已成为一种流行病。据美国疾病预防控制中心(CDC)统计,1999-2017年,美国处方阿片类药物过量导致的死亡人数接近25万人。2017年,美国卫生和公共服务部正式确认这一危机,并宣布进入公共卫生紧急状态。

强生向欧洲药品管理局提交申请,寻求扩大其IL-23单抗Tremfya用于治疗银屑病关节炎

强生已向欧洲药品管理局(EMA)提交了II型变更申请,以寻求扩大其白细胞介素-23单抗Tremfya(guselkumab)用于治疗成人活动性银屑病关节炎(PsA)。一旦获批,将成为该药物在欧盟的第二项适应症。

头对头临床试验:百济神州的BTK抑制剂Brukinsa未能击败强生/艾伯维的Imbruvica

头对头的华氏巨球蛋白血症临床试验中,百济神州的BTK抑制剂Brukinsa未能击败强生/艾伯维的竞争药物Imbruvica。华氏巨球蛋白血症是一种罕见的影响白细胞的癌症。

80亿美元!强生Risperdal败诉并要求支付天价赔偿金

美国宾夕法尼亚州费城民事诉讼法庭于费城的陪审团日前当庭宣判强生败诉并作出裁决,认为强生公司应为Nicholas Murray在服用强生抗精神病药Risperdal时出现乳腺发育异常负责,并要求强生赔偿该患者80亿美元。

强生宣布其IL-12/IL-23单抗STELARA(ustekinumab)喜获FDA批准治疗中度至重度活动性溃疡性结肠炎

强生公司宣布,美国食品和药物管理局(FDA)批准STELARA(优斯)用于治疗中度至重度活动溃疡性结肠炎成年患者。该新适应症的批准是基于关键的3期UNIFI临床试验,该临床试验实现了其临床缓解的主要终点。UNIFI的结果表明,与安慰剂相比,使用STELARA进行治疗可在患有中度至重度活动性溃疡性结肠炎(UC)的成年患者中实现并维持临床缓解。

强生的抑郁症药物Spravato鼻喷雾剂,在欧洲获批

强生的抑郁症药物Spravato(esketamine)鼻喷雾剂,已在欧洲被批准用于治疗患有抗药性重度抑郁症的成年人。欧盟委员会(EC)批准该药物与选择性5-羟色胺再摄取抑制剂(SSRI)或5-羟色胺和去甲肾上腺素再摄取抑制剂(SNRI)结合使用,用于对至少两种抗抑郁药没有反应的成年患者。